- Home
- LAB vs DIAX Comparison
LAB vs DIAX Comparison
Compare LAB & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LAB | DIAX |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Finance Companies |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.4M | 561.9M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | LAB | DIAX |
|---|---|---|
| Price | $1.48 | $15.40 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.35 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 96.6K |
| Earning Date | 02-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $169,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 79.77 | N/A |
| 52 Week Low | $0.92 | $12.80 |
| 52 Week High | $1.72 | $15.12 |
Technical Indicators
Market Signals| Indicator | LAB | DIAX |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 52.81 |
| Support Level | $1.50 | $15.42 |
| Resistance Level | $1.67 | $15.60 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 54.66 | 42.55 |
Price Performance
Historical ComparisonAbout LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.